Response of pediatric low grade gliomas to chemotherapy

Amar Gajjar, Richard L. Heideman, Edward H. Kovnar, James A. Langston, Robert A. Sanford, Edwin C. Douglass, Jesse J. Jenkins, Marc E. Horowitz, Larry E. Kun

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Thirteen patients with low grade astrocytomas were treated with alkylating agent or platinum-based chemotherapy regimens. Eleven of these patients received chemotherapy as their initial postoperative treatment modality, and 2 others as treatment for progessive disease postradiation therapy. Responses were objectively determined using CT or MRI. One patient had a complete response (CR). 6 had partial responses (PR), and 3 others had stable disease (SD) as their best response. Clinical responses paralleled those determined objectively. Chemotherapy was well tolerated with the exception of ototoxicity in 4 patients treated with cisplatin. Despite good initial responses. 5 of 6 patients who received no further treatment postchemotherapy (4 PR, 1 SD) developed progressive disease 5-13 months after completing chemotherapy. The remaining 4 patients with objective responses or stable disease (1 CR, 2 PR, 1 SD), all received further postchemotherapy treatment with radiation therapy or surgery, and have not demonstrated disease progression. Our experience suggests that alkylator or platinum-based chemotherapy can successfully delay the growth of these locally infiltrative neoplasms, and should be considered in their primary management. Despite the experience of others, further therapy appears necessary in patients with residual CT or MRI abnormalities postchemotherapy.

Original languageEnglish (US)
Pages (from-to)113-120
Number of pages8
JournalPediatric Neurosurgery
Volume19
Issue number3
DOIs
StatePublished - Jan 1 1993

Fingerprint

Glioma
Pediatrics
Drug Therapy
Alkylating Agents
Platinum
Therapeutics
Astrocytoma
Cisplatin
Disease Progression
Radiotherapy
Growth
Neoplasms

Keywords

  • Astrocytoma
  • Chemotherapy
  • Low grade

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Clinical Neurology

Cite this

Gajjar, A., Heideman, R. L., Kovnar, E. H., Langston, J. A., Sanford, R. A., Douglass, E. C., ... Kun, L. E. (1993). Response of pediatric low grade gliomas to chemotherapy. Pediatric Neurosurgery, 19(3), 113-120. https://doi.org/10.1159/000120714

Response of pediatric low grade gliomas to chemotherapy. / Gajjar, Amar; Heideman, Richard L.; Kovnar, Edward H.; Langston, James A.; Sanford, Robert A.; Douglass, Edwin C.; Jenkins, Jesse J.; Horowitz, Marc E.; Kun, Larry E.

In: Pediatric Neurosurgery, Vol. 19, No. 3, 01.01.1993, p. 113-120.

Research output: Contribution to journalArticle

Gajjar, A, Heideman, RL, Kovnar, EH, Langston, JA, Sanford, RA, Douglass, EC, Jenkins, JJ, Horowitz, ME & Kun, LE 1993, 'Response of pediatric low grade gliomas to chemotherapy', Pediatric Neurosurgery, vol. 19, no. 3, pp. 113-120. https://doi.org/10.1159/000120714
Gajjar A, Heideman RL, Kovnar EH, Langston JA, Sanford RA, Douglass EC et al. Response of pediatric low grade gliomas to chemotherapy. Pediatric Neurosurgery. 1993 Jan 1;19(3):113-120. https://doi.org/10.1159/000120714
Gajjar, Amar ; Heideman, Richard L. ; Kovnar, Edward H. ; Langston, James A. ; Sanford, Robert A. ; Douglass, Edwin C. ; Jenkins, Jesse J. ; Horowitz, Marc E. ; Kun, Larry E. / Response of pediatric low grade gliomas to chemotherapy. In: Pediatric Neurosurgery. 1993 ; Vol. 19, No. 3. pp. 113-120.
@article{d8df6a53e97b458b94c0773effa9c054,
title = "Response of pediatric low grade gliomas to chemotherapy",
abstract = "Thirteen patients with low grade astrocytomas were treated with alkylating agent or platinum-based chemotherapy regimens. Eleven of these patients received chemotherapy as their initial postoperative treatment modality, and 2 others as treatment for progessive disease postradiation therapy. Responses were objectively determined using CT or MRI. One patient had a complete response (CR). 6 had partial responses (PR), and 3 others had stable disease (SD) as their best response. Clinical responses paralleled those determined objectively. Chemotherapy was well tolerated with the exception of ototoxicity in 4 patients treated with cisplatin. Despite good initial responses. 5 of 6 patients who received no further treatment postchemotherapy (4 PR, 1 SD) developed progressive disease 5-13 months after completing chemotherapy. The remaining 4 patients with objective responses or stable disease (1 CR, 2 PR, 1 SD), all received further postchemotherapy treatment with radiation therapy or surgery, and have not demonstrated disease progression. Our experience suggests that alkylator or platinum-based chemotherapy can successfully delay the growth of these locally infiltrative neoplasms, and should be considered in their primary management. Despite the experience of others, further therapy appears necessary in patients with residual CT or MRI abnormalities postchemotherapy.",
keywords = "Astrocytoma, Chemotherapy, Low grade",
author = "Amar Gajjar and Heideman, {Richard L.} and Kovnar, {Edward H.} and Langston, {James A.} and Sanford, {Robert A.} and Douglass, {Edwin C.} and Jenkins, {Jesse J.} and Horowitz, {Marc E.} and Kun, {Larry E.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1159/000120714",
language = "English (US)",
volume = "19",
pages = "113--120",
journal = "Pediatric Neurosurgery",
issn = "1016-2291",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Response of pediatric low grade gliomas to chemotherapy

AU - Gajjar, Amar

AU - Heideman, Richard L.

AU - Kovnar, Edward H.

AU - Langston, James A.

AU - Sanford, Robert A.

AU - Douglass, Edwin C.

AU - Jenkins, Jesse J.

AU - Horowitz, Marc E.

AU - Kun, Larry E.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Thirteen patients with low grade astrocytomas were treated with alkylating agent or platinum-based chemotherapy regimens. Eleven of these patients received chemotherapy as their initial postoperative treatment modality, and 2 others as treatment for progessive disease postradiation therapy. Responses were objectively determined using CT or MRI. One patient had a complete response (CR). 6 had partial responses (PR), and 3 others had stable disease (SD) as their best response. Clinical responses paralleled those determined objectively. Chemotherapy was well tolerated with the exception of ototoxicity in 4 patients treated with cisplatin. Despite good initial responses. 5 of 6 patients who received no further treatment postchemotherapy (4 PR, 1 SD) developed progressive disease 5-13 months after completing chemotherapy. The remaining 4 patients with objective responses or stable disease (1 CR, 2 PR, 1 SD), all received further postchemotherapy treatment with radiation therapy or surgery, and have not demonstrated disease progression. Our experience suggests that alkylator or platinum-based chemotherapy can successfully delay the growth of these locally infiltrative neoplasms, and should be considered in their primary management. Despite the experience of others, further therapy appears necessary in patients with residual CT or MRI abnormalities postchemotherapy.

AB - Thirteen patients with low grade astrocytomas were treated with alkylating agent or platinum-based chemotherapy regimens. Eleven of these patients received chemotherapy as their initial postoperative treatment modality, and 2 others as treatment for progessive disease postradiation therapy. Responses were objectively determined using CT or MRI. One patient had a complete response (CR). 6 had partial responses (PR), and 3 others had stable disease (SD) as their best response. Clinical responses paralleled those determined objectively. Chemotherapy was well tolerated with the exception of ototoxicity in 4 patients treated with cisplatin. Despite good initial responses. 5 of 6 patients who received no further treatment postchemotherapy (4 PR, 1 SD) developed progressive disease 5-13 months after completing chemotherapy. The remaining 4 patients with objective responses or stable disease (1 CR, 2 PR, 1 SD), all received further postchemotherapy treatment with radiation therapy or surgery, and have not demonstrated disease progression. Our experience suggests that alkylator or platinum-based chemotherapy can successfully delay the growth of these locally infiltrative neoplasms, and should be considered in their primary management. Despite the experience of others, further therapy appears necessary in patients with residual CT or MRI abnormalities postchemotherapy.

KW - Astrocytoma

KW - Chemotherapy

KW - Low grade

UR - http://www.scopus.com/inward/record.url?scp=0027152260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027152260&partnerID=8YFLogxK

U2 - 10.1159/000120714

DO - 10.1159/000120714

M3 - Article

VL - 19

SP - 113

EP - 120

JO - Pediatric Neurosurgery

JF - Pediatric Neurosurgery

SN - 1016-2291

IS - 3

ER -